Discover recent press, blog posts and announcements from Sequoia.
News
Sequoia Reinsurance Services offers a portfolio of reinsurance solutions to support companies as they work to manage medical risk
and contain costs.
Sarepta Duchenne gene therapy wins broader use from FDA
Click here to download PDF
READ MORE
The Dangers, Cost of Weight Loss Drugs and How…
Click here to download PDF
READ MORE
Bristol Myers secures another FDA go-ahead for Breyanzi, this…
Click here to download PDF
READ MORE
BMS CAR-T Therapy Wins FDA Approval for Expanded Use…
Click here to download PDF
READ MORE
Pfizer will charge $3.5M for its first FDA- approved…
Click here to download PDF
READ MORE
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple…
Click here to download PDF
READ MORE
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene…
Click here to download PDF
READ MORE
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as…
Click here to download PDF
READ MORE
US FDA grants accelerated approval for Iovance’s skin cancer…
Click here to download PDF
READ MORE
Vertex, CRISPR’s gene-editing therapy Casgevy wins early FDA nod…
Click here to download PDF
READ MORE
FDA approves world’s first CRISPR-based medicine for sickle cell
Click here to download PDF
READ MORE
Self Insurer – Wellness Program RESET
Click here to download PDF
READ MORE
Sequoia and IOA Re Announce Expansion into Personal Accident…
Leading medical stop loss and managed care writers expand product offering with Everest
READ MORE
The Sequoia Branch Advisory Statement on Claim Payment Integrity
Click here to download PDF
READ MORE
Mesoblast Plans New GvHD Trial After Another FDA Rejection
Click here to download PDF
READ MORE
FDA blesses CellTrans’ Lantidra, the first cell therapy for…
Click here to download PDF
READ MORE
BioMarin finally secures FDA approval of hemophilia gene therapy
Click here to download PDF
READ MORE
First Duchenne gene therapy approved by FDA for young…
Click here to download PDF
READ MORE
Self Insurer – Employers Prioritize Behavioral Health
Click here to download PDF
READ MORE
FDA approves Krystal gene therapy for rare wound disorder
Click here to download PDF
READ MORE
NSM Insurance Group Acquires ELMC Subsidiaries from J.C. Flowers…
Click here to download PDF
READ MORE
US allows use of Gamida’s therapy in blood cancer…
Click here to download PDF
READ MORE
Ferring Receives Approval from U.S. FDA for Adstiladrin for…
Click here to download PDF
READ MORE
Self Insurer – Inflation Impacts Healthcare Costs and Self-Insured…
Click here to download PDF
READ MORE
Australia’s CSL prices hemophilia gene therapy at $3.5 million
Click here to download PDF
READ MORE
FDA approves J&J’s BCMA-targeted bispecific for multiple myeloma
Click here to download PDF
READ MORE
Self Insurer – Stop Loss companies and reinsurers help…
Click here to download PDF
READ MORE
Bluebird wins FDA approval of gene therapy for rare…
Click here to download PDF
READ MORE
Bluebird’s $2.8 million gene therapy becomes most expensive drug…
The U.S. Food and Drug Administration on Wednesday approved bluebird bio’s (BLUE.O) gene therapy for patients with a rare disorder…
READ MORE
SIIA- Reinsurance Market Update
Click here to download PDF
READ MORE
Bristol’s Breyanzi wins broader FDA nod, bringing CAR-T showdown…
The FDA has cleared Breyanzi to treat newly relapsed or refractory large B-cell lymphoma, less than three months after Yescarta…
READ MORE
BioMarin Delays Planned FDA Filing
Click here to download PDF
READ MORE
Medicaid Best Price 101
Click here to download PDF
READ MORE
Yescarta® Receives U.S. FDA Approval as First CAR T-cell…
Click here to download PDF
READ MORE
Sequoia – Cell & Gene Therapy Risk Solutions
Click here to download PDF
READ MORE
Sequoia Branch Bill Review Extended ICU LOS
Sequoia Branch Bill Review Extended ICU LOS
READ MORE
Phase 3 Trial of Hemophilia A Gene Therapy SB-525
Phase 3 Trial of Hemophilia A Gene Therapy SB-525
READ MORE
Sequoia Branch Oncology Claims Negotiation
Sequoia Branch Oncology Claims Negotiation
READ MORE
Novartis’ Kymriah fails to meet primary goal in non-Hodgkin…
Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial
READ MORE
New data show BioMarin’s troubled hemophilia gene therapy continues…
New data show BioMarin’s troubled hemophilia gene therapy continues to fade, opening room for rivals – Endpoints News
READ MORE
Bluebird cleared by FDA to resume studies of sickle…
Bluebird cleared by FDA to resume studies of sickle cell gene therapy
READ MORE
FDA approval sets stage for a showdown between Alexion…
FDA approval sets stage for a showdown between Alexion and Apellis BioPharma Dive
READ MORE
FDA approves ADC Therapeutics antibody drug conjugate in B-cell…
FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma - MedCity News
READ MORE
U.S. Food and Drug Administration Approves Bristol Myers Squibbs…
U.S. Food and Drug Administration Approves Bristol Myers Squibbs and bluebird bios Abecma (idecabtagene vicleucel)
READ MORE
Gilead’s Kite keeps adding to CAR-T Yescarta’s bag of…
Gilead’s Kite keeps adding to CAR-T Yescarta’s bag of tricks
READ MORE
Bristol Myers finally wins FDA approval for cancer cell…
Bristol Myers finally wins FDA approval for cancer cell therapy
READ MORE
CMS Issues Final Rule to Empower States, Manufacturers, and…
CMS Issues Final Rule to Empower States, Manufacturers, and Private Payers
READ MORE
Sequoia Branch Industry Leading Client Savings 2020
Sequoia Branch Industry Leading Client Savings 2020
READ MORE
Sequoia Reinsurance Services LLC Announces Agreement with Everest Reinsurance…
Click here to download PDF.
READ MORE
Sequoia Branch CAR T-Cell Insights
Click here to download PDF.
READ MORE
Sequoia Underwriting Administrator Announcement
Click here to download PDF.
READ MORE
COVID-19 Case Branch Savings
COVID-19 Case Branch Savings
READ MORE
NICU Case Branch Savings
NICU Case Branch Savings
READ MORE
COVID Patients Testing Positive
COVID Patients Testing Positive
READ MORE
Sequoia Presents: The Impact of COVID-19 – Focused Claims…
Sequoia Presents: The Impact of COVID-19 - Focused Claims Review with Optum
READ MORE
How Much More Than Medicare
How Much More Than Medicare
READ MORE
Potential Costs of Coronavirus Treatment
Potential Costs of Coronavirus Treatment
READ MORE
Mass. Outlines Deal For A $2 Million Drug: Pay…
Mass. Outlines Deal For A $2 Million Drug: Pay Only If It Works
READ MORE
Reinsurance Market Risk Drivers and Pipeline 2020
Provided Content is password protected. Click Read More!
READ MORE
Branch Claim Payment Integrity Review
Branch Claim Payment Integrity Review
READ MORE
Accessibility and Affordability of Gene Therapy
Accessibility and Affordability of Gene Therapy
READ MORE
Doctor offers unique perspective as father of a child…
Doctor offers unique perspective as father of a child with rare genetic disease
READ MORE
Market Insight Specialty Pharmacy
Market Insight Specialty Pharmacy
READ MORE
Market Insight Gene and Immuno – Therapy
Market Insight Gene and Immuno - Therapy
READ MORE
Long Term Acute Care (LTAC) Hospitals
Long Term Acute Care (LTAC) Hospitals
READ MORE
Market Insight-Hemophilia
Market Insight-Hemophilia
READ MORE
Market Insight ICER Pharmacy Rebates
Market Insight ICER Pharmacy Rebates
READ MORE
Sequoia Reinsurance Launches, Focused on HMO Reinsurance and Provider…
MINNEAPOLIS, June 14, 2018 /PRNewswire/ — Sequoia Reinsurance LLC (“Sequoia”) announced today that it has launched operations focused on HMO reinsurance and provider…
READ MORE
New Reinsurance Firm to Offer Some Employer Stop-Loss
A new, Minneapolis-based health reinsurance firm says it will offer specialized employer stop-loss arrangements, without defining exactly what those arrangements…
READ MORE
Something Happened to U.S. Drug Costs in the 1990s
Two decades ago, the costs began rising well beyond that of other nations, and in recent years have shot up…
READ MORE
Branch Program Claim Payment Integrity Review
Branch Program Claim Payment Integrity Review
READ MORE